Introduction
Permissivity to HIV-1 replication is very low in resting CD4 þ T cells, but is greatly enhanced upon cell activation (Siliciano and Greene, 2011) . This shift towards a favorable environment for viral replication is largely driven by widespread transcriptional changes, including those induced by altered microRNA (miRNA) expression. MiRNAs are short, non-coding RNAs which mediate post-transcriptional repression of gene expression, and are estimated to regulate over 50% of human protein-coding genes (Pasquinelli, 2012) . Recent studies have shown that many microRNAs (miRNAs) downregulated following CD4 þ T cell activation can inhibit HIV-1 replication, either via targeting of the HIV-1 RNA itself (Huang et al., 2007; Nathans et al., 2009) , or via the repression of cellular co-factors of HIV such as Tat partner Cyclin T1 (Triboulet et al., 2007; Sung and Rice, 2009; Chiang et al., 2012) . We hypothesized that miRNAs which are upregulated following CD4 þ T cell activation may, on the converse, act to potentiate HIV-1 replication. We found that miR-132 fulfills both of these conditions, and as such, is, to the best of our knowledge, the first miRNA identified to increase HIV-1 replication.
Results and discussion
We previously performed miRNA expression profiling in resting and PHA-activated CD4 þ T cells isolated from four healthy donors (Chiang et al., 2012) , and observed that miR-132 was very highly upregulated following activation (Fig. 1A) . In order to confirm the microarray results, we measured miR-132 levels in five additional healthy donors, and found a two to five-fold increase in miR-132 levels after activation with anti-CD3/28 (Fig. 1B) . MiR-132 levels also increased to comparable levels after PBMCs isolated from relatively young (age 25 and under) and elderly (60 and over) HIV-positive donors were treated with PHA ( Fig. 1C) , suggesting that activation-induced increases in miR-132 expression are unaffected by age or HIV status.
Transfection of synthetic miR-132 into Jurkat cells followed by infection with replication-competent NL4.3 virus resulted in increased viral replication (Fig. 2) . MiR-132 also appeared to affect HIV-1 latency, as its over-expression reactivated virus in 2D10 cells (Fig. 3) , a clonal Jurkat cell line latently infected with virus carrying attenuated Tat and destabilized GFP with a shortened half-life, which better reflects fluctuations in viral gene expression (Pearson et al., 2008) . TNF-a treatment of the 2D10 cell line re-activates latent virus in a very high percentage of cells, with reestablishment of latency occurring over the course of a few days. MiR-132 transfection prior to TNF-a treatment of 2D10 cells was found to delay viral return into latency (data not shown).
Methyl-CpG binding protein 2 (MeCP2), a transcriptional regulatory protein (Guy et al., 2011) , was previously shown to be a miR-132 target in the murine brain (Klein et al., 2007; Alvarez-Saavedra et al., 2011 þ T cells were isolated from five healthy blood donors, and a portion of the cells was activated with anti-CD3/28 beads. Two days later, total RNA was isolated and quantitative real-time PCR was performed to measure miR-132 levels relative to U6 snRNA; values presented were normalized relative to miR-132 levels in the resting cells of Donor 5. MiR-132 levels were found to be significantly higher following CD4 þ T cell activation (Student's t-test, p o0.02). (C) Relative miR-132 levels were measured as above in resting or PHA-activated PBMCs from HIV-positive, viremic donors; no significant difference in miR-132 levels was observed between activated cells from young versus elderly donors (Student's t-test, p 40.05). Jurkat cells led to a decrease in MeCP2 mRNA and protein levels ( Fig. 4A and B) , indicating that MeCP2 is also a target of miR-132 in T cells. Furthermore, we found that knockdown of MeCP2 also enhanced NL4.3 production in Jurkat cells, as measured by luciferase expression of the TZM-bl reporter line infected with the virus-containing supernatant (Fig. 5A ). Neither transfection of MeCP2 siRNA nor miR-132 affected cell proliferation, as measured by an MTT assay (Fig. 4C) . Unlike miR-132, MeCP2 siRNA was unable to re-activate latent virus in 2D10 cells (Fig. 3) , indicating that additional targets of miR-132 may be contributing to its ability to disrupt viral latency.
These data suggest that miR-132 potentiates viral replication, in a manner which may be partially dependent on its ability to suppress MeCP2. It has previously been shown that miR-132 is highly upregulated following infection with Kaposi's sarcoma herpesvirus, herpes simplex virus-1, and human cytomegalovirus, and that miR-132 suppresses the host antiviral innate immune response by targeting the transcriptional co-activator p300 (Lagos et al., 2010) . While p300 is a known co-factor of HIV-1 transcription (Nekhai and Jeang, 2006) , it is also possible that modulation of p300 expression serves to regulate the innate immune response during HIV-1 infection. However, in the current study we did not test this hypothesis, nor the effects of other miR-132 targets on HIV-1 replication. Interestingly, along with being upregulated by CD4 þ T cell activation, miR-132 expression has also been shown to increase in murine brain tissue following cocaine administration (Hollander et al., 2010; Nudelman et al., 2010) , and as cocaine has previously been shown to potentiate HIV-1 replication (Bagasra and Pomerantz, 1993; Peterson et al., 1991; Roth et al., 2002) , this suggests that miR-132 may influence HIV-1 infection in cocaine abusers. While recent work has provided evidence that miR-217 can enhance Tat transactivation by down-regulating SIRT1 (Zhang et al., 2012) , our findings comprise the first report of a miRNA which can enhance HIV-1 replication and re-activate latent virus.
Materials and methods

Resting CD4
þ T cells were isolated from healthy donor blood (Gulf Coast Regional Blood Center, Houston, TX) using the RosetteSep human CD4 þ T cell enrichment cocktail (STEMCELL); activated cells were removed using CD30 Microbeads (Miltenyi Biotec). Cells were activated with phytohemagglutinin (PHA) treatment (10 ng/mL) or CD3/28 Dynabeads (Invitrogen) and cultured in RPMI supplemented with 10% fetal bovine serum (FBS). Banked, frozen PBMCs from HIV-positive donors were thawed and half were left untreated, while the other half was treated with 1 mg/mL PHA; cells were harvested after two days.
Total RNA was isolated using either the miRVana miRNA isolation kit (Applied Biosystems) or the miRNeasy Mini Kit (Qiagen), and qRT-PCR was performed using the TaqMan microRNA reverse transcription kit, TaqMan microRNA assays, and Universal PCR Master Mix (all from Applied Biosystems).
MiRNAs and siRNAs used were as follows: Pre-miR miR-132 Precursor or Pre-miR negative control ]1 (Applied Biosystems), MeCP2 siRNA (5 0 -AAGCAUGAGCCCGUGCAGCCA-3 0 ) (Bakker et al., 2002) , and AllStars Negative Control siRNA (Qiagen). Jurkat cells were transfected with the indicated miRNAs and siRNAs using Lipofectamine RNAiMAX reagent (Invitrogen), followed by infection with NL4.3 virus (the NL4.3 plasmid was obtained from Malcolm Martin through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, and virus was produced via plasmid transfection into 293T cells). Cells were washed 24 h post-infection, and virus production was measured 48 h post-infection either by quantifying p24 levels in the supernatant via enzyme-linked immunosorbent assay (ELISA) (Zeptometrix) or by using virus-containing supernatant to infect TZM-bl cells, with luciferase expression measured using the Luciferase Assay System (Promega). 2D10 cells were transfected with miRNA as above, and GFP expression was monitored by flow cytometry.
MTT assays were performed two days post-transfection using Cell Proliferation Kit I (Roche). 
